Edgestream Partners L.P. Boosts Stock Holdings in Amgen Inc. $AMGN

Edgestream Partners L.P. boosted its position in Amgen Inc. (NASDAQ:AMGN) by 169.9% in the first quarter, Holdings Channel.com reports. The firm owned 8,376 shares of the medical research company’s stock after acquiring an additional 5,273 shares during the quarter. Edgestream Partners L.P.’s holdings in Amgen were worth $2,947,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Dogwood Wealth Management LLC lifted its holdings in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after buying an additional 55 shares during the period. Anfield Capital Management LLC grew its holdings in Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after acquiring an additional 70 shares during the period. Tower View Wealth Management LLC raised its position in Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company’s stock worth $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC lifted its holdings in Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after acquiring an additional 32 shares during the period. Finally, Ares Financial Consulting LLC purchased a new stake in shares of Amgen during the 4th quarter worth $34,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insiders Place Their Bets

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.85% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion recommending broader use of Repatha to reduce cardiovascular risk in high-risk adults without a prior heart attack or stroke. The recommendation, based on Phase 3 data showing fewer major cardiovascular events, could expand Repatha’s addressable market in Europe. Amgen Wins Backing in Europe for Broader Repatha Use
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, payable September 11 to shareholders of record on August 21. The ongoing payout, equivalent to $10.08 annually and an indicated yield of about 2.6%, supports the stock’s income appeal and signals continued confidence in cash generation. Amgen Announces 2026 Third Quarter Dividend
• Positive Sentiment: Amgen launched its first Amgen Scholars Program in India at IIIT Hyderabad. Although not a near-term financial driver, the initiative may strengthen the company’s research talent pipeline and scientific relationships. First Amgen Scholars Program in India Launches
• Neutral Sentiment: Wall Street’s attention is centered on second-quarter results. Amgen has a history of earnings beats, but investors will scrutinize product-sales trends, guidance and progress on MariTide, making the report a significant near-term catalyst. Amgen Q2 Earnings Preview
• Negative Sentiment: Barclays raised its price target to $360 but retained a Hold rating. With the target below the recent trading level, the update reinforces concerns that much of Amgen’s positive outlook may already be reflected in the shares. Barclays Boosts Amgen Price Target

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Truist Financial increased their price target on shares of Amgen from $327.00 to $340.00 and gave the company a “hold” rating in a report on Tuesday, July 7th. Royal Bank Of Canada reissued a “positive” rating on shares of Amgen in a report on Thursday, June 18th. Barclays increased their target price on shares of Amgen from $350.00 to $360.00 and gave the company an “equal weight” rating in a report on Wednesday. Argus reduced their price target on shares of Amgen from $400.00 to $375.00 and set a “buy” rating for the company in a research report on Wednesday, May 20th. Finally, Wall Street Zen lowered Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, June 27th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, fifteen have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $357.00.

Amgen Trading Down 0.6%

Shares of Amgen stock opened at $385.16 on Friday. Amgen Inc. has a fifty-two week low of $269.77 and a fifty-two week high of $398.00. The firm has a market cap of $207.87 billion, a PE ratio of 26.80, a P/E/G ratio of 3.90 and a beta of 0.41. The business’s fifty day moving average is $356.60 and its two-hundred day moving average is $353.77. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analysts’ expectations of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the firm earned $4.90 earnings per share. Analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be given a dividend of $2.52 per share. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a yield of 2.6%. Amgen’s dividend payout ratio is 70.15%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.